MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Funding Strategies for Architects (Private Equity, Venture & Risk Capital)
Intermediaries: Risk Capital (Angel, Seed, Venture Capital, SPAC, Strategic Corporate, Private Equity, Banking)
Intermediaries: Hedge Funds
*Hedge Funds (Medical, Biotechnology Focused)
BAKER BROTHERS ADVISORS LP
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)*
Organization & Developments: BioMarin
Parents
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)*
Children
*Products: Naglazyme® for MPS VI, Aldurazyme® for MPS I, Firdapse™ (currently approved in the EU only) for LEMS, KUVAN® Tablets for PKU
*The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates.
2018: BioMarin Keeps The FDA Approval Train Rolling - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
2018: BioMarin Pharmaceutical Is A Promising Orphan Disease Player In 2018 - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
2018: Biomarin Pharmaceuticals (BMRN)_Biotech Forum Daily Digest For February 26th
2019: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy – Endpoints News
2019: BioMarin Pharmaceutical: A Robust Fundamental Pick In 2019_seekingalpha.com
2019: BioMarin Rebounds_seekingalpha.com
2019: BioMarin_Lining Up A Single In This Mid-Cap Biotech Stock
2019: BioMarin's hemophilia gene therapy is about to face a crucial test. 9 things to know
2019: Brighter Days For BioMarin_seekingalpha.com
2020: BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock Plunges
2020: Deep Genomics hits the partnering ground running with BioMarin deal
2020: Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
2021: BioMarin: Voxzogo Approval Could Trigger A Lengthy Bull Run For Cash Rich Biotech
2021: BioMarin's Hemophilia A Treatment: An Assessment
2022: BioMarin lays off 120 staffers to 'simplify' the company while FDA reviews its big gene therapy
2022: BioMarin Pharmaceutical: Leader In Rare Disease Innovation_seekingalpha.com
2024: Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
2024: BioMarin Pharmaceutical Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: BioMarin Pharmaceutical: A Volatile But Growing Trajectory_ seekingalpha.com
2024: BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/202
2024: BioMarin to lay off 170 staffers after pipeline reorg
2024: BioMarin: Challenges Mount, But Sale Rumors Make For A Risky 'Buy' Call
2024: BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
2024: BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?_ seekingalpha.com
2025: BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations
2025: BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy_ seekingalpha.com
Organization & Developments: BioMarin (Archives 2012-2017)
Jumps
*Key People: BioMarin
Finance & Acquisition: BioMarin